SK281214B6 - Perorálny kvapalný farmaceutický prostriedok, spôsob jeho výroby a jeho použitie - Google Patents

Perorálny kvapalný farmaceutický prostriedok, spôsob jeho výroby a jeho použitie Download PDF

Info

Publication number
SK281214B6
SK281214B6 SK1004-96A SK100496A SK281214B6 SK 281214 B6 SK281214 B6 SK 281214B6 SK 100496 A SK100496 A SK 100496A SK 281214 B6 SK281214 B6 SK 281214B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
paroxetine
composition according
agents
potassium
Prior art date
Application number
SK1004-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK100496A3 (en
Inventor
Graham Stanley Leonard
David Cooper
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK100496A3 publication Critical patent/SK100496A3/sk
Publication of SK281214B6 publication Critical patent/SK281214B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SK1004-96A 1994-02-03 1995-01-30 Perorálny kvapalný farmaceutický prostriedok, spôsob jeho výroby a jeho použitie SK281214B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation
PCT/EP1995/000319 WO1995020964A1 (fr) 1994-02-03 1995-01-30 Compositions liquides buvables contenant un resinate de paroxetine

Publications (2)

Publication Number Publication Date
SK100496A3 SK100496A3 (en) 1996-12-04
SK281214B6 true SK281214B6 (sk) 2001-01-18

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1004-96A SK281214B6 (sk) 1994-02-03 1995-01-30 Perorálny kvapalný farmaceutický prostriedok, spôsob jeho výroby a jeho použitie

Country Status (34)

Country Link
US (1) US5811436A (fr)
EP (1) EP0742715B1 (fr)
JP (1) JP4445590B2 (fr)
CN (1) CN1074922C (fr)
AP (2) AP611A (fr)
AT (1) ATE178489T1 (fr)
AU (1) AU682091B2 (fr)
BG (1) BG62843B1 (fr)
BR (1) BR9507055A (fr)
CA (1) CA2182593A1 (fr)
CZ (1) CZ285128B6 (fr)
DE (1) DE69508924T2 (fr)
DK (1) DK0742715T3 (fr)
DZ (1) DZ1850A1 (fr)
ES (1) ES2129806T3 (fr)
FI (1) FI118205B (fr)
GB (1) GB9402029D0 (fr)
GR (1) GR3030131T3 (fr)
HK (1) HK1012288A1 (fr)
HU (1) HUT75941A (fr)
IL (1) IL112521A (fr)
MA (1) MA23441A1 (fr)
MX (1) MX9603203A (fr)
MY (1) MY113036A (fr)
NO (1) NO307954B1 (fr)
NZ (1) NZ278891A (fr)
OA (1) OA10446A (fr)
PL (1) PL178331B1 (fr)
RO (1) RO116342B1 (fr)
RU (1) RU2136281C1 (fr)
SK (1) SK281214B6 (fr)
TW (1) TW436296B (fr)
WO (1) WO1995020964A1 (fr)
ZA (1) ZA95776B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EE03970B1 (et) 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1250937B1 (fr) * 2001-04-09 2009-05-13 Rohm And Haas Company Dissolution contrôlée de substances actives
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
ES2261726T3 (es) * 2001-08-09 2006-11-16 Smithkline Beecham Plc Composicion que comprende paroxetina y una sal glicirricinato farmaceuticamente aceptable.
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (fr) * 2004-08-18 2006-02-23 Synthon B.V. Compositions liquides de paroxetine
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1948646A2 (fr) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科(北京)研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
US8758779B2 (en) 2009-06-25 2014-06-24 Wockhardt Ltd. Pharmaceutical composition of duloxetine
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
ES2588008T3 (es) 2010-05-19 2016-10-28 Astellas Pharma Inc. Composición farmacéutica que contiene solifenacina
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
CA3128377A1 (fr) 2019-02-01 2020-08-06 University Of South Carolina Compositions de pyridine bicyclique et procedes pour leur utilisation pour la therapie du cancer
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Also Published As

Publication number Publication date
PL315679A1 (en) 1996-11-25
US5811436A (en) 1998-09-22
RU2136281C1 (ru) 1999-09-10
DK0742715T3 (da) 1999-10-18
ES2129806T3 (es) 1999-06-16
BG62843B1 (bg) 2000-09-29
AP611A (en) 1997-09-03
CZ285128B6 (cs) 1999-05-12
AP536A (en) 1996-09-26
AU682091B2 (en) 1997-09-18
BR9507055A (pt) 1997-09-02
HUT75941A (en) 1997-05-28
GB9402029D0 (en) 1994-03-30
MA23441A1 (fr) 1995-10-01
CZ229396A3 (en) 1997-01-15
IL112521A (en) 1999-09-22
NZ278891A (en) 1998-01-26
AP9500715A0 (en) 1995-04-30
FI118205B (fi) 2007-08-31
RO116342B1 (ro) 2001-01-30
CN1140411A (zh) 1997-01-15
DE69508924T2 (de) 1999-10-21
HU9602151D0 (en) 1996-09-30
PL178331B1 (pl) 2000-04-28
DE69508924D1 (de) 1999-05-12
FI963051A (fi) 1996-08-01
CA2182593A1 (fr) 1995-08-10
DZ1850A1 (fr) 2002-02-17
MX9603203A (es) 1997-03-29
TW436296B (en) 2001-05-28
JPH09508402A (ja) 1997-08-26
BG100763A (bg) 1997-03-31
ATE178489T1 (de) 1999-04-15
FI963051A0 (fi) 1996-08-01
ZA95776B (en) 1996-08-01
GR3030131T3 (en) 1999-07-30
WO1995020964A1 (fr) 1995-08-10
CN1074922C (zh) 2001-11-21
JP4445590B2 (ja) 2010-04-07
HK1012288A1 (en) 1999-07-30
MY113036A (en) 2001-11-30
AP9600839A0 (en) 1996-07-31
EP0742715A1 (fr) 1996-11-20
NO963244D0 (no) 1996-08-02
OA10446A (en) 2002-03-26
IL112521A0 (en) 1995-05-26
AU1536895A (en) 1995-08-21
EP0742715B1 (fr) 1999-04-07
NO307954B1 (no) 2000-06-26
SK100496A3 (en) 1996-12-04
NO963244L (no) 1996-08-02

Similar Documents

Publication Publication Date Title
SK281214B6 (sk) Perorálny kvapalný farmaceutický prostriedok, spôsob jeho výroby a jeho použitie
BG63862B1 (bg) Фармацевтични състави, съдържащи инхибитори на моноаминоксидаза в
CA2011063C (fr) Compose pharmaceutique de nicardipine pour administration parenterale
EP2838510A1 (fr) Solution d'atomoxétine
US20080125453A1 (en) Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
EP1543826B1 (fr) Solution aqueous concentree de ambroxol
SK284847B6 (sk) Perorálny vodný roztok obsahujúci ako aktívnu zložku 4-amino-5-chlór-2,3-dihydro-N-[1-(3-metoxypropyl)-4-piperidyl]-7- benzofuránkarboxamid a spôsob jeho prípravy
NZ542218A (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid
ES2250211T3 (es) Disolucion oral que contiene galantamina y un agente edulcorante.
KR20010101173A (ko) 높은 함량의 트리히드록시-에틸-루틴을 지닌 트록세루틴및 이의 제조 방법
EP1345599A1 (fr) Traitement d'un trouble obsessionnel-compulsif
CN116999417A (zh) 包含丹皮酚和罗布麻宁的液体制剂
GR1009069B (el) Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη
US20070219253A1 (en) Decongestant / antihistaminic / expectorant compositions
JP3232503B2 (ja) 光に安定なベンジルアルコール誘導体含有水溶液
RU2190396C1 (ru) Сироп бромгексина
WO2014027976A1 (fr) Compositions pharmaceutiques aqueuses topiques de flurbiprofène et chlorhexidine
US20040082665A1 (en) Method for treating stress or tension
BG65307B1 (bg) Лекарствена форма, съдържаща хлорхексидин